Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025

Reuters

08/14

Jaguar Health Inc. Reports 35% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025

Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559495423"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559495423\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559495423?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559495423","market":"nz","top_or_hot":-1,"title":"Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Reports 35% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-14 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Inc. Reports 35% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL6T7wX3:1","article_id":"2559495423","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559495423","pubTimestamp":1755172874,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi, Gelclair, and Canalevia-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"translate_title":"捷豹健康公司。报告2025年第二季度收入增长35%，处方药净收入较2025年第一季度增长36%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Inc. Reports 35% Increase in Q2 2025 Revenue, Prescription Products Net Revenue Up 36% from Q1 2025\n    \n\n        Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060956) on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}